Delegates at a conference in the US this week are hearing about early results of a trial of a new personalized ovarian cancer vaccine that offers new hope for the large number of patients who relapse after treatment. Three-quarters of trial patients who received the new two-step immunotherapy appeared to respond to the treatment, including one patient who achieved completed remission, say researchers from the Perelman School of Medicine at the University of Pennsylvania...
More...
More...